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A new woman-controlled contraceptive vaginal ring: 
a global step forward
More than 40 years ago, the development of 
contraceptive vaginal rings began, based on the fact that 
the vaginal epithelium can absorb steroid hormones and 
the capacity of elastomers to release these hormones at 
almost constant rates.1 The growing interest in woman-
controlled contraceptive methods has supported and 
accelerated the process.
The main advantages of contraceptive vaginal 
rings are their effectiveness, ease of use, user control, 
nearly constant release rate allowing for lower doses 
of hormones, greater bioavailability, and good 
cycle control compared with oral contraceptives.2 
There are two types of contraceptive vaginal ring 
on the market—Nuvaring (Merck Sharp & Dohme; 
Kenilworth, NJ, USA), which releases etonogestrel and 
ethinylestradiol for 1 month, and Progering (Silesia; 
Santiago, Chile), which is a 3-month progesterone-
only ring for use during breastfeeding. Both rings are 
expensive, require refrigeration, and are not readily 
available in low-income and middle-income countries 
(LMICs). Therefore, reducing costs and expanding the 
availability of contraceptive vaginal rings is important, 
as is development of those with longer durations that 
do not need refrigeration, which would increase the 
contraceptive options for women globally.
In The Lancet Global Health, David Archer and 
colleagues3 report the results of two non-randomised, 
open-label, single-arm phase 3 trials of a ring-
shaped, contraceptive vaginal system developed by 
the Population Council, which releases a consistent 
amount of segesterone acetate and ethinylestradiol 
over 1 year of cyclic use and does not require 
refrigeration. These trials were done at US and non-US 
sites and evaluated the efficacy of the contraceptive 
vaginal system and return to menses or pregnancy 
after use.3 The results showed the efficacy and safety of 
this contraceptive system, with an overall Pearl Index 
of 2·98 (95% CI 2·13–4·06) and a contraceptive efficacy 
rate of 97·5% on the basis of a life-table analysis. All 
participants who were followed up reported return 
to menses or pregnancy within 6 months. As this 
contraceptive vaginal system is effective for a full 
year of cyclic use and does not require refrigeration 
during periods of non-use, this is likely to facilitate 
accessibility and help to address a global unmet 
contraceptive need.3
Gemzel-Danielson and colleagues4 reported that the 
1-year segesterone acetate 150 µg and ethinylestradiol 
13 µg daily contraceptive vaginal system represents a 
new long-term, user-controlled, and procedure-free 
contraceptive option with a safety profile similar to 
other combined hormonal contraceptives.4 The new 
contraceptive vaginal system is a safe and effective 
combined hormonal contraceptive that is under a 
woman’s control and was considered acceptable by 
women who participated in the clinical trials.3
Addressing the unmet contraceptive need remains 
a global high priority, as illustrated by recent reports 
assessing progress in meeting contraceptive demands 
since the Family Planning 2020 Summit.5,6 Cahill and 
colleagues5 reported that between 2012 and 2017 
the number of women of reproductive age who were 
married or in a union and using modern methods of 
contraception increased by 28·8 million, with success 
stories including rapid increases in use in Kenya, 
Mozambique, Malawi, Lesotho, Sierra Leone, Liberia, 
and Chad relative to what was expected in 2012. 
However, they also underlined that global levels of 
contraceptive prevalence mask the diversity in progress 
at the country level.5 Ahmed and colleagues6 showed 
that annual percentage increases in contraceptive use 
were above the average of 1·4 percentage points needed 
to achieve the 2012 Family Planning Summit goal to 
provide family planning to an additional 120 million 
women by 2020.6,7 However, progress was shown to 
be slow in several countries where the annual rate of 
change was lower than 1 percentage point, far below the 
target needed to achieve the goal.6
Multiple factors play a part in contraceptive use and 
need to be addressed. Availability and affordability of a 
portfolio of modern contraceptive methods, including 
this new birth control option, might help address the 
persistent, unmet, global contraceptive need. This new 
contraceptive vaginal ring was approved by the US Food 
and Drug Administration in August, 2018, and thus 
represents the first ring not requiring refrigeration to 
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offer women a whole year of contraceptive protection, 
contributing to equity and choice.8
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